Inovio Pharmaceuticals (INO) Projected to Release Earnings on Wednesday

Inovio Pharmaceuticals (NASDAQ:INO) will likely be posting its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect Inovio Pharmaceuticals to announce earnings of ($0.25) per share and revenue of $0.5330 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. On average, analysts expect Inovio Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Inovio Pharmaceuticals Trading Down 4.8%

Shares of INO stock opened at $0.66 on Wednesday. Inovio Pharmaceuticals has a 1 year low of $0.56 and a 1 year high of $2.98. The firm’s 50 day moving average is $1.10 and its 200-day moving average is $1.34. The firm has a market capitalization of $54.55 million, a price-to-earnings ratio of -0.46 and a beta of 1.52.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INO. Focus Partners Wealth bought a new position in Inovio Pharmaceuticals during the third quarter worth about $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 5,894 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 18,160 shares during the period. Raymond James Financial Inc. boosted its stake in Inovio Pharmaceuticals by 4,396.0% during the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 16,309 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new position in Inovio Pharmaceuticals during the 3rd quarter worth approximately $41,000. Institutional investors own 26.79% of the company’s stock.

Analyst Ratings Changes

INO has been the topic of several research reports. Wall Street Zen downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, June 21st. Piper Sandler reissued an “overweight” rating and issued a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday. HC Wainwright dropped their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a research report on Monday, June 1st. Finally, Weiss Ratings raised Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $3.25.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.